荆花胃康联合PPI三联疗法治疗幽门螺杆菌相关慢性胃炎的效果  

Efficacy of Jinghua Weikang combined with PPI triple therapy on chronic gastritis associated with Helicobacter pylori

作　　者：王二伟 李筱婷 WANG Er-wei;LI Xiao-ting(Emergency Department,Xi＇an XD Group Hospital,Xi＇an 710077,China)

机构地区：[1]西安市西电集团医院急诊科,陕西西安710077

出　　处：《临床医学研究与实践》2018年第34期44-46,共3页Clinical Research and Practice

摘　　要：目的评价荆花胃康联合PPI三联疗法治疗幽门螺杆菌相关慢性胃炎的临床效果。方法将我院消化内科2015年3月至2018年3月收治的100例幽门螺杆菌相关慢性胃炎患者作为研究对象,根据入院先后顺序将其分为对照组和试验组,各50例。对照组予以兰索拉唑+阿莫西林+克拉霉素+枸橼酸铋钾治疗,试验组予以荆花胃康+兰索拉唑+阿莫西林+克拉霉素治疗,比较两组患者治疗前、后的主症(腹胀、嗳气、上腹痛、纳差)积分、幽门螺杆菌根除率、临床疗效、不良反应发生情况及治疗前、后的心理状态和生活质量。结果治疗后,两组患者的主症积分均降低,且试验组明显低于对照组(P<0.05)。试验组的幽门螺杆菌根除率明显高于对照组(P<0.05)。试验组的治疗总有效率高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗后,两组患者SF-36评分均升高,HAMA评分均降低,且试验组明显优于对照组(P<0.05)。结论荆花胃康联合PPI三联疗法治疗幽门螺杆菌相关慢性胃炎疗效可靠,药效发挥迅速,不良反应少,能够有效减轻疾病对患者心理状态的影响,改善患者生活质量。Objective To evaluate the clinical efficacy of Jinghua Weikang combined with PPI triple therapy onchronic gastritis associated with Helicobacter pylori. Methods A total of 100 patients with chronic gastritis associated withHelicobacter pylori admitted in digestive medicine department of our hospital from March 2015 to March 2018 wereselected as study objects. According to the order of admission, they were divided into control group and experimentalgroup, with 50 cases in each group. The control group was treated with lansoprazole＋amoxicillin＋clarithromycin＋potassiumcitrate, and the experimental group was treated with Jinghua Weikang ＋lansoprazole ＋amoxicillin ＋clarithromycin. Thescores of main symptoms （abdominal distension, belching, upper abdominal pain, anorexia） before and after treatment,eradication rate of Helicobacter pylori, clinical efficacy, total incidence of adverse reactions, psychological status andquality of life before and after treatment were compared between the two groups. Results After treatment, the scores ofmain symptoms in the both groups decreased, and those of the experimental group were significantly lower than thecontrol group（P〈0.05）. The eradication rate of Helicobacter pylori in the experimental group was significantly higher thanthat in the control group （P〈0.05）. The total effective rate of treatment in the experimental group was higher than that inthe control group（P约0.05）. There was no significant difference in the total incidence of adverse reactions between the twogroups（P〉0.05）. After treatment, the SF-36 scores in the both groups increased, and HAMA scores decreased, and those of the experimental group were significantly better than the control group （P〈0.05）. Conclusion The combined use ofJinghua Weikang and PPI triple therapy on chronic gastritis associated with Helicobacter pylori has advantages of reliableefficacy, rapid efficacy and less adverse reactions, it can effectively reduce the impact of the disease on patients＇ men

关 键 词：幽门螺杆菌相关慢性胃炎 荆花胃康 PPI三联疗法 

分 类 号：R573[医药卫生—消化系统]